{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-031882","form_type":"8-K","ticker":"IMNN","cik":"0000749647","company_name":"Imunon, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.778135+00:00","generated_at":"2026-05-31T09:30:35.853048+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Imunon reports positive Phase 2 OS data for IMNN-001; net loss narrows in Q2 2024","bullets":["Q2 net loss of $4.8M ($0.51/share) vs $5.6M ($0.61/share) in Q2 2023; operating expenses down 8%.","Positive OVATION 2 topline: 11.1-month median OS improvement (HR=0.74) in ITT; 15.7-month gain in per-protocol (HR=0.64).","Phase 3 study of IMNN-001 planned to start Q1 2025 after End-of-Phase 2 FDA meeting.","Raised $10M gross ($9M net) in July 2024 registered direct offering; cash + investments $5.3M at June 30, funding into Q3 2025.","IMNN-101 Phase 1 COVID booster trial enrolling; topline data expected by year-end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-031882","json":"https://secwatch.observer/filing/0001493152-24-031882.json","markdown":"https://secwatch.observer/filing/0001493152-24-031882.md","text":"https://secwatch.observer/filing/0001493152-24-031882.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/749647/000149315224031882/0001493152-24-031882-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/749647/000149315224031882/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:30:35.853048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}